ReviewDiagnostics (Basel, Switzerland)2026
Emerging Diagnostic Strategies for Oral Cancer and Oral Potentially Malignant Disorders: A PRISMA-Guided Scoping Review.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesEarly detection remains the most decisive factor in improving outcomes for oral cancer and oral potentially malignant disorders. However, reliance on conventional biopsy-based pathways presents some practical and biological limitations. This scoping review aimed to map recent advances in non- and minimally invasive diagnostic approaches and to clarify how these innovations are being positioned within clinical workflows.
methodsFollowing PRISMA-ScR guidance, PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language original studies published between 2020 and 2025. Two independent reviewers screened and charted data on technologies, biomarkers, sampling sources, and clinical applications. Forty-nine studies were included. The literature clustered around four main domains: enhanced cytology (including liquid-based platforms and DNA ploidy analysis), multilayer liquid biopsy strategies (miRNA, cfDNA/ctDNA, methylation panels, and autoantibodies), optical and nanotechnology-based systems (Raman/SERS and sensor platforms), and artificial intelligence-driven decision support tools.
resultsAcross modalities, a shared emphasis on rapid triage, risk stratification, and follow-up monitoring was evident. Nonetheless, variability in sampling, processing, analytical thresholds, and reporting standards limited cross-study comparability.
conclusionsRecent innovations point toward integrated, panel-based diagnostic models. Broader clinical adoption will require methodological standardization and robust multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.